Generation of Islet Specific T Follicular Regulatory Like Cells for Autologous Cell Therapy of Type 1 Diabetes

用于 1 型糖尿病自体细胞治疗的胰岛特异性滤泡调节性 T 细胞的产生

• 批准号: 10437608
• 负责人: Puchong Thirawatananond
• 金额: $ 4.09万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-05-16 至 2026-05-15
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10437608
• 关键词: Adoptive Cell Transfers; Adoptive Transfer; Affinity; Age; Animal Disease Models; Animal Model; Antigens; Autoantibodies; Autoimmune Diseases; Autoimmunity; Autologous; B-Cell Activation; B-Lymphocytes; BLR1 gene; Back; Beta Cell; Biological Models; Bystander Suppression; C-Peptide; CD3 Antigens; CD4 Positive T Lymphocytes; CXCL13 gene; Cell Therapy; Cells; Characteristics; Chemotaxis; Clinical Management; Confocal Microscopy; Data; Dendritic Cells; Dependence; Detection; Development; Diabetes Mellitus; Diabetes prevention; Diagnosis; Disease Progression; Educational process of instructing; Engineering; Enzyme-Linked Immunosorbent Assay; Exhibits; Female; Florida; Flow Cytometry; Gene Transfer; Generations; Genes; Genome; Growth; Helper-Inducer T-Lymphocyte; Histology; Homing; Immune; Immune Targeting; Immune response; Immunoglobulin Class Switching; Immunoglobulin Somatic Hypermutation; Immunology; Immunomodulators; In Vitro; Inbred BALB C Mice; Inbred NOD Mice; Incidence; Infiltration; Infusion procedures; Injections; Institutes; Insulin; Insulin-Dependent Diabetes Mellitus; Interruption; Investigational Therapies; Islets of Langerhans; Knock-in; Location; Mature B-Lymphocyte; Measures; Mediating; Mesentery; Methods; Migration Assay; Modality; Modeling; Mus; Onset of illness; Organ; Ovalbumin; Pancreas; Patients; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Physicians; Play; Population; Prediabetes syndrome; Principal Investigator; Production; Prognosis; Protocols documentation; Rattus; Regulatory T-Lymphocyte; Reporting; Research; Research Design; Research Personnel; Risk; Role; Scientist; Serum; Site; Specificity; Stains; Structure of beta Cell of islet; Structure of germinal center of lymph node; T-Cell Receptor; T-Cell Receptor Genes; TNFSF5 gene; Technical Expertise; Testing; Therapeutic; Training; Transgenic Mice; Transgenic Organisms; Translating; Universities; Writing; cancer therapy; cellular engineering; chemokine receptor; clinical translation; cytokine; design; diabetogenic; diphtheria toxin receptor; early phase clinical trial; engineered T cells; experience; experimental study; genome editing; glucose monitor; immune activation; immunoregulation; improved; in vitro testing; in vivo; insulin secretion; insulitis; islet; islet cell antibody; lymph nodes; pre-clinical; prevent; promoter; repaired; response; skills; targeted treatment; trafficking

Project Summary/Abstract Type 1 diabetes (T1D) is an autoimmune disease leading to pancreatic beta cell destruction and lifelong dependence on exogenous insulin injections. Immunomodulatory agents that aim to reverse beta cell autoimmunity have been shown to delay T1D diagnosis but cannot halt the decline of C-peptide levels that reflect insulin production. Autologous cell therapy (ACT) is an investigational therapy that aims to restore the immune set point back to tolerance by infusion of ex vivo expanded regulatory T cells (Tregs). Tregs are responsible for downregulating the immune response and their absence in animal models of diabetes leads to accelerated disease progression. Early clinical trials of ACT, however, show that transfused Tregs persist for years in patients but were ineffective in preventing C-peptide decline. This project proposes to generate islet specific T follicular regulatory (Tfr) cells from Tregs through gene editing to improve their utility as ACT for T1D. Tfr cells are a specialized subset of Tregs that act in the germinal centers of lymph nodes where mature B cells are activated by T follicular helper (Tfh) cells. Early B cell activation is an important step in T1D prognosis as the detection of class-switched islet autoantibodies in the pre-diabetic phase predicts onset of disease. Therefore, creating Tfr-like cells represents a potential avenue of T1D prevention through suppression of Tfh-mediated activation. The following Specific Aims outline the objectives for utilizing genome targeting to produce Tfr-like cells as potential cellular therapies of T1D. In Aim 1, islet reactive Tregs will be produced through non-viral genome editing to knock in islet reactive TCR in the TCR locus. Engineered Tregs will be tested in vitro for islet antigen reactivity and tested in vivo through adoptive transfer into NOD mice to determine its effects on diabetes incidence. In Aim 2, the Tfr cell characteristic chemokine receptor CXCR5 will be knocked in the Rosa26 locus of islet reactive Tregs and tested for responsivity to CXCL13. Engineered CXCR5-positive islet reactive Tregs will be transferred into NOD mice to assess diabetes incidence and Treg trafficking to the pancreas and pancreatic lymph nodes. The proposed training will take place at the University of Florida Diabetes Institute under the guidance of Dr. Todd Brusko and Dr. Michael Haller. The training plan will provide the applicant with research design and technical skills in autoimmunity, cell engineering, and diabetes models as well as professional skills in teaching and scientific writing to facilitate growth as an independent investigator.

项目摘要/摘要 1型糖尿病（T1D）是一种自身免疫性疾病，导致胰腺β细胞破坏和终生 对外源胰岛素注射的依赖。旨在逆转β细胞的免疫调节剂 自身免疫性已显示会延迟T1D诊断，但不能停止C肽水平的下降 反映胰岛素的产生。自动细胞疗法（ACT）是一种研究疗法，旨在恢复 免疫设定点可以通过输注过体内扩展的调节性T细胞（Tregs）来回到耐受性。 Treg是 负责下调免疫反应及其在糖尿病动物模型中的缺失导致 加速疾病进展。然而，ACT的早期临床试验表明，被输血的Treg持续存在 患者的年份，但在预防C肽下降方面无效。 该项目提议从Tregs通过基因生成胰岛特异性T卵泡调节（TFR）细胞 编辑以改善其作为T1D行为的实用性。 TFR细胞是在Treg中的专门子集 淋巴结的生发中心，其中成熟的B细胞被T卵泡辅助器（TFH）细胞激活。早期b 细胞激活是T1D预后的重要一步，因为检测类切换的胰岛自身抗体 糖尿病前期预测疾病的发作。因此，创建TFR样细胞代表潜力 通过抑制TFH介导的激活，预防T1D的途径。 以下特定目的概述了利用基因组靶向产生TFR样细胞的目标 作为T1D的潜在细胞疗法。在AIM 1中，胰岛反应性Treg将通过非病毒基因组产​​生 编辑以敲击TCR基因座中的胰岛反应性TCR。工程treg将在体外测试胰岛抗原 反应性并通过过继转移到NOD小鼠中在体内进行测试，以确定其对糖尿病的影响 发病率。在AIM 2中，TFR细胞特征趋化因子受体CXCR5将在Rosa26基因座中敲击 胰岛反应性Treg，并测试了对CXCL13的响应。设计的CXCR5阳性胰岛反应性Tregs 将转移到点头小鼠中，以评估糖尿病的发病率和Treg贩运胰腺，然后 胰腺淋巴结。 拟议的培训将在佛罗里达大学糖尿病研究所举行 托德·布鲁斯科（Todd Brusko）博士和迈克尔·哈勒（Michael Haller）博士。培训计划将为申请人提供研究设计和 自身免疫，细胞工程和糖尿病模型以及教学专业技能的技术技能 和科学写作，以促进作为独立研究者的成长。